University of North Carolina, Greensboro, NC, USA.
Adv Exp Med Biol. 2021;1264:47-65. doi: 10.1007/978-3-030-57369-0_4.
In recent years, an increasing number of investigations has demonstrated the therapeutic potential of molecules targeting the endocannabinoid system. Cannabinoids of endogenous, phytogenic, and synthetic nature have been assessed in a wide variety of disease models ranging from neurological to metabolic disorders. Even though very few compounds of this type have already reached the market, numerous preclinical and clinical studies suggest that cannabinoids are suitable drugs for the clinical management of diverse pathologies.In this chapter, we will provide an overview of the endocannabinoid system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.
近年来,越来越多的研究表明,靶向内源性大麻素系统的分子具有治疗潜力。内源性、植物源性和合成来源的大麻素已在从神经学到代谢紊乱等多种疾病模型中进行了评估。尽管这类化合物中只有极少数已经上市,但大量的临床前和临床研究表明,大麻素是治疗多种疾病的合适药物。在这一章中,我们将概述内源性大麻素系统在某些生理病理条件下的情况,重点关注神经、肿瘤和代谢紊乱。我们将讨论在实验模型中被评估为有潜在治疗作用的大麻素,重点介绍最成功的化学实体及其向临床应用的前景。